An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

Bibliography

• Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007;120:936-9
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cohen MD, Cush JJ, Unresolved issues in identifying and overcoming inadequate responses in rheumatoid arthritis: weighing the evidence. J Rheumatol 2007;35(Suppl 81):4-30
   Google Scholar
• Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5
   PubMed Web of Science ®Google Scholar
• Bajpai M. Fostamatinib, a SYK inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009;12(13):174-85
   Google Scholar
• Rigel news release. Available from: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1391043&highlight [Last accessed 8 July 2010]
   Google Scholar
• Portola news release. Available from: http://www.portola.com/pdfs/Portola_syk_Ph_1_news_release_3.22.10.pdf [Last accessed 8 July 2010]
   Google Scholar
• Pine PR, Chang B, Schoettler N, Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel SYK inhibitor. Clin Immunol 2007;124(3):244-57
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58(11):3309-18
   Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, An oral spleen tyrosine kinase (SYK) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12
   PubMed Web of Science ®Google Scholar
• Rigel Pharmaceuticals, Inc. Preparation of prodrugs of 2,4-pyrimidinediamine compounds and their use for mediating diseases via activitation of Fc receptor signaling cascades. WO06078846; 2006
   Google Scholar
• Norman P. A novel SYK kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011. Expert Opin Ther Patents 2009;19(10);1469-72
   Google Scholar
• Rigel Pharmaceuticals, Inc. Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction. WO03063794; 2003
   Google Scholar
• Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal SYK-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115(4):791-6
   Google Scholar
• Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamines for use in the treatment or prevention of autoimmune diseases. WO05012294; 2005
   Google Scholar
• Sweeny DJ, Li W, Clough J, Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010; 38(7):1166-76
   Google Scholar
• Rigel Pharmaceuticals, Inc. Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. WO05016893; 2005
   Google Scholar
• Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their preparation and biological use. WO08064274; 2008
   Google Scholar
• Rigel Pharmaceuticals, Inc. Preparation of pyrimidine-2,4-diamines as RET kinase inhibitors for treatment of cell proliferative disorders. WO09003136; 2009
   Google Scholar
• Yamanouchi Pharmaceutical Co., Ltd., Preparation of novel pyrimidine-5-carboxamide derivatives as tyrosinase inhibitors. WO9931073; 1999
   Google Scholar
• Yamanouchi Pharmaceutical Co., Ltd., Preparation of novel heterocyclic carboxamide derivatives as spleen tyrosine kinase inhibitors. WO0075113; 2000
   Google Scholar
• Hisamichi H, Naito R, Toyoshima A, Synthetic studies on novel SYK inhibitirs. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 2005;13:4936-51
   PubMed Web of Science ®Google Scholar
• Kissei Pharmaceutical Co., Ltd., Preparation of imidazopyrimidines as tyrosine kinase inhibitors. JP04203748; 2004
   Google Scholar
• Kissei Pharmaceutical Co., Ltd., Preparation of triazolopyrimidines, their pharmaceutical compositions, and their use for treatment of protein tyrosine kinase-related diseases. JP04238296; 2004
   Google Scholar
• Kissei Pharmaceutical Co., Ltd., Pyrazolo[1,5-a]pyrimidine derivatives, prophylactic or therapeutic agents containing them for protein tyrosine kinase-related diseases, and combination drugs containing them. JP05008581; 2005
   Google Scholar
• Hirabayashi A, Mukaiyama H, Kobayashi H, A novel Syk family kinase inhibitor: Design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorg Med Chem 2008;16:7347-57
   PubMed Web of Science ®Google Scholar
• Hirabayashi A, Mukaiyama H, Kobayashi H, Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective SYK family kinases inhibitors. Bioorg Med Chem 2008;16:9247-60
   Google Scholar
• Portola Pharmaceuticals, Inc. Diaminopyrimidinecarboxamide derivatives as inhibitors of SYK protein kinase and their preparation. WO09136995; 2009
   Google Scholar
• Liddle J, Atkinson F, Barker M, Discovery of a highly potent, selective, and orally bioavailable SYK inhibitor, American Chemical Society 32nd Annual National Medicinal Chemistry Symposium (abstract 54); June 2010, Minneapolis, MN
   Google Scholar
• Glaxo Group Ltd, Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase. WO10097248; 2010
   Google Scholar
• Portola Pharmaceuticals, Inc. Preparation of diaminopyrimidinylcarboxamide derivatives for use as SYK and JAK kinases inhibitors. WO09145856; 2009
   Google Scholar
• Novartis AG, Preparation of 2,4-di(arylamino)-pyrimidine-5-carboxamides as JAK kinases inhibitors. WO08009458; 2008
   Google Scholar
• Portola Pharmaceuticals, Inc. Protein kinase inhibitors. US7705004; 2010
   Google Scholar
• Portola Pharmaceuticals, Inc., Preparation of pyrimidine, pyrrolopyrimidine and purine-based analogs as inhibitors of protein kinases. WO09131687; 2009
   Google Scholar
• Lilly news release. Available from: http://newsroom.lilly.com/releasedetail.cfm?releaseid=498928 [Last accessed 27 August 2010]
   Google Scholar
• Capuano VL. Obviousness of chemical compounds: the “lead compound” concept. Intellect Property Today 2007;33-5
   Google Scholar